Methods for treating gout
The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.
1. A method of treating gout in a patient, the method comprising administering a PEGylated uricase and azathioprine (AZA) to the patient; wherein the PEGylated uricase is administered weekly for a total of 3 weeks at a dose of 8 mg protein and then administered bi-weekly at a dose of 8 mg protein, wherein the AZA is dosed at about 1.25-5.5 mg/kg daily.
2. The method of claim 1 , further comprising administering prednisone.
3. The method of claim 1 , wherein the AZA is administered orally.
4. The method of claim 3 , wherein the AZA dose is about 1.25 mg/kg daily for one week followed by about 2.5 mg/kg daily.
5. The method of claim 1 , wherein AZA administration is initiated 2 weeks prior to the first PEGylated uricase dose.
6. The method of claim 1 , wherein the patient has a serum uric acid level of >6 mg/dL before beginning treatment.
7. The method of claim 1 , wherein the patient has a co-morbid condition selected from the group consisting of hypertension, dyslipidemia, chronic kidney disease, diabetes, coronary artery disease, arrhythmia, and cardiac failure.
8. The method of claim 1 , comprising measuring a level of one or more of trough PEGylated uricases, anti-PEGylated uricase antibodies, and anti-monomethyoxypoly(ethylene glycol) (PEG) antibodies.
9. The method of claim 1 , wherein the administration of the PEGylated uricase is effective in reducing a tophus burden in the patient.
10. The method of claim 9 , wherein:
(a) at least 1 tophus is completely resolved as determined by comparison of photography of a tophus before and after administration of the PEGylated uricase;
(b) no new tophi appear after the administration of the PEGylated uricase; and
(c) no single tophus shows progression after the administration of the PEGylated uricase.
11. The method of claim 1 , wherein the serum uric acid level is reduced to less than, or equal to, 6 mg/dL.
12. A method of treating gout in a patient weighing less than 120 kg, comprising administering a PEGylated uricase and azathioprine (AZA) to the patient, wherein the treatment comprises a tolerizing dose regimen, wherein, during the tolerizing dose regimen, the PEGylated uricase is administered weekly for 3 weeks at a dose of 8 mg protein, and the AZA is administered on a daily basis at about 1.25-5.5 mg/kg starting 2 weeks prior to the first PEGylated uricase dose; and, after the tolerizing dose regimen, the PEGylated uricase is administered every 2 weeks at a dose of 8 mg protein, and the AZA is administered on a daily basis at about 1.25-5.5 mg/kg.
13. The method of claim 12 wherein the AZA dose is about 1.25 mg/kg.
14. A method of treating gout in a patient weighing ≥120 kg, comprising administering a PEGylated uricase and azathioprine (AZA) to the patient, wherein the treatment comprises a tolerizing dose regimen; wherein, during the tolerizing dose regimen, the PEGylated uricase is administered weekly for 3 weeks at a dose of 8 mg protein, 12 mg protein, or 16 mg protein, and the AZA is administered on a daily basis at about 1.25-5.5 mg/kg starting 2 weeks prior to the first PEGylated uricase dose; and, after the tolerizing dose regimen, the PEGylated uricase is administered every 2 weeks at a dose of 8 mg protein, and the AZA is administered on a daily basis at about 1.25-5.5 mg/kg.
15. The method of claim 14 wherein the AZA dose is about 1.25 mg/kg.
16. The method of claim 14 wherein, during the tolerizing dose regimen, the PEGylated uricase is administered weekly for 3 weeks at a dose of 8 mg.